Trials / Completed
CompletedNCT05677685
VISUPRIME® Eye Drops
Multicentre Randomized Double-blind Trial of VISUPRIME® Eye Drops to be Evaluated in Preventing the Conjunctival Bacterial Load in Patients Undergoing to Anti-VEGF Injection
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- VISUfarma SpA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study purpose is to assess the efficacy of VISUPRIME® eye drops in preventing the conjunctival bacterial load in patients undergoing to anti-VEGF injection.
Detailed description
Multicentre, double-masked, placebo-controlled randomized 1:1 of the VISUPRIME® treatment in patients undergoing intravitreal anti-VEGF injection.
Conditions
- Macular Degeneration, Age Related
- Myopic Choroidal Neovascularisation
- Proliferative Diabetic Retinopathy
- Diabetic Macular Edema
- Macular Edema of Right Retina (Diagnosis)
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | VISUPRIME | twice daily |
| DEVICE | Placebo | twice daily |
Timeline
- Start date
- 2023-06-22
- Primary completion
- 2024-01-23
- Completion
- 2024-01-23
- First posted
- 2023-01-10
- Last updated
- 2024-07-19
Locations
6 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT05677685. Inclusion in this directory is not an endorsement.